New Data Presented Demonstrates Ovulatory Effect of Teva Women's Health, Inc. (TEVA)’s Investigational 28-Day Oral Contraceptive
5/8/2013 10:45:01 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NORTH WALES, Pa.--(BUSINESS WIRE)--Teva Women’s Health, a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., presented new data on ovulation inhibition and ovarian activity from a Phase I clinical trial of Teva’s investigational 28-day oral contraceptive (OC) (150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days, followed by 7 days of 10 mcg EE), an investigational monthly regimen. The results were presented at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG).
Help employers find you! Check out all the jobs and post your resume.
comments powered by